<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180843</url>
  </required_header>
  <id_info>
    <org_study_id>04/6741</org_study_id>
    <nct_id>NCT00180843</nct_id>
  </id_info>
  <brief_title>Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease</brief_title>
  <official_title>Assessment of Ventilation-perfusion Abnormalities in Patients With Smoking-related Airways Disease in Stable Condition and the Effect of Bronchodilator Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects undergo history, examination, lung function assessment after informed consent has
      been obtained. All subjects will undergo ventilation-perfusion scans. If there first scan is
      normal they will undergo a second and final scan four weeks later. If abnormal they will
      undergo two further scans with either nebulized bronchodilator or nebulized saline prior to
      their second and third scans. Each time they will have repeat lung function tests prior to
      scanning. We will examine the regional changes in ventilation and perfusion and there
      relationship to lung function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As in Brief description
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of resources research fellow left
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>scan grade</measure>
    <time_frame>post scan</time_frame>
    <description>previously validated grading score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung function</measure>
    <time_frame>pre scan</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>saline control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nebulized saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>salbutamol and ipratropium bromide nebules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>salbutamol 2.5 mg and ipratropium bromide 0.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol + ipratropium bromide nebules</intervention_name>
    <arm_group_label>salbutamol and ipratropium bromide nebules</arm_group_label>
    <other_name>albuterol</other_name>
    <other_name>Ventolin</other_name>
    <other_name>Atrovent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nebulized saline</intervention_name>
    <arm_group_label>saline control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FEV1 &lt; 70% predicted at baseline on spirometry

          -  significant smoking history or alpha 1 antitrypsin deficiency

          -  no evidence of current infection or restrictive lung disease

        Exclusion Criteria:

          -  history of other significant respiratory disease

          -  significant respiratory infection within 6 weeks

          -  history of significant physical or mental illness rendering them unfit for the study
             in the opinion of the investigator

          -  taken part in any other research within the past 12 months, or received exposure to
             ionizing radiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip W Ind, MB BChir MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Hammersmith</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Hammersmith Campus</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 21, 2013</last_update_submitted>
  <last_update_submitted_qc>September 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imperial College London</investigator_affiliation>
    <investigator_full_name>Philip Ind</investigator_full_name>
    <investigator_title>Consultant Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

